NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, July 29, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

WaterRising Institute talks OUTFRONT partnership.

Ashley Mastronardi delivers the pre-market update on July 29th

  • Investors await the Federal Reserve’s decision on interest rates, which is due today at 2 p.m. ET.
    • The latest data shows that two-thirds of traders expect interest rates to hold steady at the target range of 3.5% to 3.75%.
    • Fed Chair Kevin Warsh will speak at 2:30 p.m. ET.
  • IMC Rare Earths will begin trading NYSE American.
    • The company raised $20 million in its IPO, pricing four million shares at $5 each.
    • Roberts & Ryan CEO Ed D’Alessandro will join NYSE Live to discuss its role as the deal’s bookrunner.
  • WaterRising Institute Founder + CEO Alicia Douglas will join NYSE Live to discuss its recent partnership with OUTFRONT Media.
    • The organization is on a mission to make modern water infrastructure visible to capital markets and society.

Opening Bell
ACORE celebrates its 25th anniversary of powering investment in American clean energy

Closing Bell
T. Rowe Price celebrates the T. Rowe Price Active Crypto ETF (NYSE Arca: TKNZ)

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Third Coast Bancshares at the NYSE on July 28.
Third Coast Bancshares at the NYSE on July 28.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Dreame Technology Introduces 'Spring Cleaning' Promotion Campaign for Effortless Home Cleaning Solutions

SAN FRANCISCO, March 20, 2024 /PRNewswire/ — From March 20th to April 20th,…

TECNO Users Can Now Get 3 Months of Google AI Plus at No Cost on Eligible Device

The offer includes a 3-month Google AI Plus trial at no charge…

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

– ATG-022 is Antengene’s CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy.…